217 related articles for article (PubMed ID: 10382874)
41. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
Morrissey I; Robbins M; Viljoen L; Brown DF
J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
[TBL] [Abstract][Full Text] [Related]
42. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
[TBL] [Abstract][Full Text] [Related]
43. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
Loza E; Cantón R; Pascual A; Tubau F; Morosini MI; Almaraz F; Perea E; Martín R; Jones RN; Baquero F
Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
[TBL] [Abstract][Full Text] [Related]
44. In-vitro activity of PD 131628, a new quinolone antimicrobial agent.
Cooper MA; Andrews JM; Wise R
J Antimicrob Chemother; 1992 May; 29(5):519-27. PubMed ID: 1320603
[TBL] [Abstract][Full Text] [Related]
45. In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Yong DE; Cheong HJ; Kim YS; Park YJ; Kim WJ; Woo JH; Lee KW; Kang MW; Choo YS
J Korean Med Sci; 2002 Dec; 17(6):737-42. PubMed ID: 12482994
[TBL] [Abstract][Full Text] [Related]
46. Influence of moxifloxacin, comparator drugs and some fractions of pulmonary surfactant on adherence of some respiratory pathogens.
Ferrara A; Dos Santos C; Tellarini MT
Infection; 2002 Aug; 30(4):208-11. PubMed ID: 12236562
[TBL] [Abstract][Full Text] [Related]
47. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
Sun H; Chen L; Chen X; Jia X; Li N; Liu W; Tong H; Xiang R; Zhang F; Zhao H; Zhang J; Xu Y
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jan; 39(1):30-7. PubMed ID: 26792053
[TBL] [Abstract][Full Text] [Related]
48. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
Esposito S; Noviello S; Ianniello F
Chemotherapy; 2000; 46(5):309-14. PubMed ID: 10965095
[TBL] [Abstract][Full Text] [Related]
49. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
Hoogkamp-Korstanje JA; Dirks-Go SI; Kabel P; Manson WL; Stobberingh EE; Vreede RW; Davies BI
J Antimicrob Chemother; 1997 Mar; 39(3):411-4. PubMed ID: 9096192
[TBL] [Abstract][Full Text] [Related]
50. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
[TBL] [Abstract][Full Text] [Related]
51. Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates.
Gönüllü N; Aktaş Z; Salcioglu M; Bal C; Ang O
Clin Microbiol Infect; 2001 Sep; 7(9):499-503. PubMed ID: 11678934
[TBL] [Abstract][Full Text] [Related]
52. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus.
Al-Nawas B; Shah PM
J Antimicrob Chemother; 1998 Jun; 41(6):655-8. PubMed ID: 9687105
[TBL] [Abstract][Full Text] [Related]
53. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
54. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA
Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
[TBL] [Abstract][Full Text] [Related]
55. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).
Gales A; Sader H; Jones RN;
Antimicrob Agents Chemother; 2001 May; 45(5):1463-6. PubMed ID: 11302811
[TBL] [Abstract][Full Text] [Related]
56. [Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Matsuzaki K; Watabe E; Yoshimori K; Shikano M; Sato Y; Hasegawa M; Kobayashi I
Jpn J Antibiot; 2002 Dec; 55(6):800-7. PubMed ID: 12621734
[TBL] [Abstract][Full Text] [Related]
57. Comparative in vitro study of the activity of moxifloxacin and other antibiotics against 150 strains of penicillin non-susceptible Streptococcus pneumoniae and against 110 strains of ampicillin-resistant Haemophilus influenzae isolated in 1999-2000 in Spain.
Alós JI; Oteo J; Aracil B; Gómez-Garcés JL
J Antimicrob Chemother; 2001 Jul; 48(1):145-8. PubMed ID: 11418530
[No Abstract] [Full Text] [Related]
58. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance.
Boswell FJ; Andrews JM; Jevons G; Wise R
J Antimicrob Chemother; 2002 Oct; 50(4):495-502. PubMed ID: 12356793
[TBL] [Abstract][Full Text] [Related]
59. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.
MacGowan A; Rogers C; Holt HA; Wootton M; Bowker K
J Antimicrob Chemother; 2000 Jul; 46(1):73-8. PubMed ID: 10882692
[TBL] [Abstract][Full Text] [Related]
60. Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli.
Piddock LJ; Jin YF; Ricci V; Asuquo AE
J Antimicrob Chemother; 1999 Jan; 43(1):61-70. PubMed ID: 10381102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]